Premium
Serum‐derived bovine immunoglobulin isolate (SBI) as a potential therapy for inflammatory bowel disorders (IBD)
Author(s) -
Klein Gerald L,
Weaver Eric,
Shaw Audrey Lynn,
Cohn Jeffrey
Publication year - 2013
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.27.1_supplement.1079.45
Subject(s) - medicine , ulcerative colitis , lamina propria , intestinal permeability , enteropathy , barrier function , gastroenterology , diarrhea , cytokine , inflammation , irritable bowel syndrome , inflammatory bowel disease , colitis , intestinal mucosa , immunology , pathology , biology , disease , epithelium , microbiology and biotechnology
Cytokine‐mediated dysfunction of the intestinal mucosal barrier is observed during the active phase of IBD. SBI may reduce its impact by reducing excessive pro‐inflammatory cytokine expression, such as TNFα, INFγ, and interleukins (eg, IL‐1, IL‐6). For example, mdr1a knockout mice prone to intestinal mucosal barrier alterations (a genetic model for IBD) who received SBI had lower levels of IL‐6 and IL‐17 in the mucosa during the onset of colitis. Research demonstrates that SBI survives initial digestive processes, improving gastrointestinal (GI) function and morphology in a clinically significant way. Animal studies confirm SBI improves cellularity of the lamina propria of the small intestine, resulting in improved mucosal barrier function, reduced inflammation and diarrhea, and improved dietary protein utilization through increased absorption, reduced permeability and mitotic activity, increased villus heights, with improved weight gain and bone density. SBI decreased watery bowel movements and increased nutrient absorption/retention in HIV patients, and was well tolerated. Early studies in patients with IBS‐D, malnutrition or HIV enteropathy demonstrated improved GI symptoms. In toto , the accumulated evidence suggests SBI is beneficial for inflammatory GI diseases such as Crohn's and ulcerative colitis and demonstrates strongly the need for additional research. Study funded by Entera Health.